News and Trends 14 Jul 2022
Agomab bags $114 million in thriving regenerative medicine sector
The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This…
Argenx
- Latest Posts
News and Trends 21 Dec 2021
Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease
US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening…
Best in Biotech 20 Dec 2021
The Billion-Euro European Biotech Companies in 2022
Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European…
News and Trends 25 May 2021
Delayed IPOs and Market Drops Batter Biotech Stocks
Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has…
ADVERTISEMENT
Best in Biotech 11 Jan 2021
The 21 European Biotech Companies To Watch in 2021
As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies…
News and Trends 29 May 2020
Argenx Follows up Phase III Success with Giant €785M Global Offering
The Dutch biotech argenx has cashed in on recent positive phase III results by launching an enormous €784.7M ($862.5M) global…
News and Trends 26 May 2020
Argenx’s Rare Disease Treatment Strikes Gold in Phase III
The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod after the first-in-class drug improved…
News and Trends 11 Nov 2019
Argenx Raises Whopping €502M in Global Offering
The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M)…
More News! 3 Apr 2019
€21M Series A to Finance Belgian Biotech’s Regenerative Antibodies
The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to develop antibody treatments that could…
News and Trends 5 Dec 2018
Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal
Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have…
ADVERTISEMENT
More News! 19 Sep 2018
Argenx Attracts Huge €250M Investment Following Positive Phase II Trial
Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after announcing positive Phase II results…
News and Trends 14 Dec 2017
Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies
Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through…
News and Trends 11 Dec 2017
Belgian Antibody Proves Effective to Treat Myasthenia Gravis
A Phase II proof of concept study has shown that one of Argenx' antibodies is effective in treating the neuromuscular disease myasthenia gravis. …
More News! 23 Aug 2017
Dutch Biotech could treat Dyslipidemia with Belgian Nanobody
Argenx' partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach…
More News! 20 Jun 2017
Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma
argenx's 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn't been disclosed by how much…
News and Trends 22 May 2017
UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II
UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares…
ADVERTISEMENT
Infographics 13 Feb 2017
Infographic: What’s in Europe’s Immuno-oncology Pipeline?
While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer.…
News and Trends 6 Dec 2016
How is European Immuno-Oncology fighting Blood Cancer?
From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's edition of the American Society…
News and Trends 16 Feb 2016
World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies
Ablynx, the llama antibody biotech in Belgium, has now proven to be on solid ground regarding their orphan drug for a…
News and Trends 3 Feb 2016
When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease
ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody pipeline which Leo Pharma (Denmark), is…
